A Brief Intervention by Nurses to Reduce the Prescribing of Occluded Peripheral Venous Catheters in the Emergency Department (PERFEKTO)

May 7, 2026 updated by: University Hospital, Rouen

Peripheral venous catheters are frequently inserted in hospitals, with approximately 25 million placed annually in France (HAS data, 2005). The occluded peripheral venous catheter with extension tubing has become the standard in some emergency departments, offering advantages such as patient mobility, the ability to perform repeated blood draws, and the administration of intravenous medications. A 2018 meta-analysis revealed that one in three devices was unnecessary. The placement of a occluded peripheral venous is associated with a more painful insertion, higher cost, and an increased risk of infection and thromboembolism, and blood samples obtained via the occluded peripheral venous catheter are more often hemolyzed than those obtained by direct venipuncture.

Communication between physicians and nurses is essential to ensure optimal patient care. A brief intervention by the nurse when a physician prescribes a occluded peripheral venous catheter can help clarify the appropriateness of this prescription, which could lead to reduced pain for the patient, time savings for healthcare providers, and material cost savings for the hospital.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

1680

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients assigned a triage score of 3A, 3B, or 4 according to the French triage scale, or 3 or 4 according to the CIMU triage scale, by the triage nurse
  • Patients with a blood draw order involving the placement of an occluded catheter
  • Age 18 years or older
  • Patients who have read and understood the information sheet
  • Patients who have given their verbal consent to participate in the study
  • Patients enrolled in a social security program

Exclusion Criteria:

  • Patients admitted to the emergency department with a pre-existing intravenous line
  • Patients treated by the Mobile Emergency and Resuscitation Unit outside the hospital
  • Patients with a blocked catheter who did not undergo an initial blood draw
  • Patient with known neurocognitive disorders incompatible with informed consent
  • Pregnant or breastfeeding woman
  • Patient under legal guardianship (guardianship or conservatorship) or patient deprived of liberty
  • Patient refusing to participate in the study
  • Patient participating in another interventional research study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Questions for the prescriber
Once the nurse has received the doctor's order for a blood draw with a KTO, she will ask the prescribing physician: Is the KTO being prescribed for: the administration of medication? The injection of a contrast agent? A second blood draw? For each question, there are three possible answers: Yes? No? Maybe?
Other: question for the prescriber
Once the nurse has received the doctor's order for a blood draw with a KTO, she will ask the prescribing physician: Is the KTO being prescribed for: the administration of medication? The injection of a contrast agent? A second blood draw? For each question, there are three possible answers: Yes? No? Maybe?

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the proportion of obturator catheters placed improperly
Time Frame: day 1
Questions for the prescriber
day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between the physician's final decision and nurse activity
Time Frame: day 1
Correlation between the physician's final decision and the performance of a repeat biopsy, the administration of contrast dye, or the administration of intravenous treatment
day 1
Use of the numerical pain scale during obturator catheter placement
Time Frame: at the end of procedure (assessed up to 20 minutes)
pain during obturator catheter placement
at the end of procedure (assessed up to 20 minutes)
Micro-costing analysis
Time Frame: at the end of procedure (assessed up to 20 minutes)
Micro-costing analysis of the cost of a standard venous blood draw and a closed-catheter procedure
at the end of procedure (assessed up to 20 minutes)
Types of intravenous medications administered
Time Frame: day 1
Types of intravenous medications administered and available oral alternatives
day 1
Number of orders for obturator catheters
Time Frame: day 1
Number of orders for obturator catheters placement during the initial blood draw for each period throughout the entire enrollment period
day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Rouen

Investigators

  • Study Chair: Déborah LEBEDIEFF, MS, University Hospital, Rouen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

March 27, 2026

First Submitted That Met QC Criteria

May 7, 2026

First Posted (Actual)

May 13, 2026

Study Record Updates

Last Update Posted (Actual)

May 13, 2026

Last Update Submitted That Met QC Criteria

May 7, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2023/0302/HP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on question for the prescriber

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe